Republican Senators Request Supreme Court to Reinstate Abortion Drug Regulations
Over one hundred Republican senators are urging the Supreme Court to restore regulations concerning abortion drugs, specifically pointing out that the current policy allows mifepristone to be mailed without in-person medical oversight. They believe this practice leads to situations where women might be coerced into taking the medication.
The legal brief is spearheaded by Senator Bill Cassidy (R-LA) and also includes input from Representative Chris Smith (R-NJ), Senate Majority Leader John Thune (D), and House Speaker Mike Johnson (R-LA). They are backing Louisiana’s effort to re-establish the requirement for the drug to be dispensed in person.
This legal filing emphasizes that relaxed federal rules have made enforcement of regulations challenging. Lawmakers are particularly concerned about changes made to the FDA’s Risk Evaluation and Mitigation Strategy (REMS), which eliminated the need for in-person visits. They argue that the Biden administration’s approach “increases the risk of enforcement.”
Several troubling incidents have been cited, featuring cases where abortion pills were reportedly acquired online or administered without a woman’s consent. One notable case involved Rosalie Markesic, who claims her boyfriend ordered mifepristone and forced her to take it.
There’s a growing pro-life debate surrounding mifepristone, with some medical professionals highlighting safety issues. The lawmakers reference multiple cases, including one where a Louisiana mother allegedly procured abortion pills for her teenage daughter, leading to a medical emergency. Another highlighted scenario involved a man believed to have administered drugs to a pregnant woman without her knowledge.
Many legislators believe that the current system, allowing for online prescriptions and mail-order distribution, heightens the risk of such incidents.
They argue this policy not only diminishes safeguards but also endangers women by undermining protections against abuse. Cassidy emphasized that these safety measures need immediate reinstatement, stating, “Chemical abortion drugs kill innocent children and endanger the lives of mothers.” He calls for protective measures like in-person dispensing to be restored, supporting the Fifth Circuit’s recent ruling.
The lawsuit emerges following a favorable ruling from the 5th Circuit Court of Appeals reinstating the in-person dispensing requirement amid ongoing litigation. Lawmakers contend that the FDA has overstepped its bounds by permitting mail-order distribution, claiming it violates the Comstock Act, which forbids sending items intended for abortion through the mail.
Smith pointed out the associated risks of the drug, noting that over 10% of women experience complications such as infections and bleeding. They argue that the agency’s decision to remove in-person requirements was based on inadequate safety data, with diminished reporting standards for adverse events.
The brief also asserts that forgoing in-person consultations hampers crucial screenings, such as those for ectopic pregnancies, and makes identifying coercion or abuse more challenging.
The situation has escalated, with manufacturers Danko Laboratories and GenBiopro filing an emergency appeal to the Supreme Court, stating that the ruling is already causing significant disruptions nationwide.
Danko claims the ruling creates a chaotic environment that complicates the responsibilities of healthcare providers, patients, and pharmacies, while GenBioPro feels the order severely limits access to mail-order services—upending a system they have relied on for quite some time.
The companies are asking the Supreme Court to block the ruling during the ongoing litigation, which could influence future distribution methods for abortion pills across the country.
The Supreme Court is weighing this emergency request from the manufacturers as it deliberates over the Fifth Circuit’s order. The outcome of this case could redefine access to abortion pills nationwide, potentially determining if they can remain available by mail or require in-person medical oversight once again.
There are genuine concerns about the risks these drugs pose to women and girls, Thun remarked, urging the Supreme Court to restore the previous safety measures while the Department of Health and Human Services reviews the drugs.
